St Jude Medical Inc. (STJ): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

St Jude Medical ( STJ) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.6%. By the end of trading, St Jude Medical fell $1.18 (-1.9%) to $62.04 on heavy volume. Throughout the day, 6,009,903 shares of St Jude Medical exchanged hands as compared to its average daily volume of 2,145,500 shares. The stock ranged in price between $59.85-$63.45 after having opened the day at $63.17 as compared to the previous trading day's close of $63.22. Other companies within the Health Care sector that declined today were: Ultragenyx Pharmaceutical ( RARE), down 9.4%, Fibrocell Science ( FCSC), down 8.2%, TearLab Corpoartion ( TEAR), down 7.6% and Escalon Medical Corporation ( ESMC), down 7.4%.

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. St Jude Medical has a market cap of $17.8 billion and is part of the health services industry. Shares are up 2.0% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate St Jude Medical a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Apricus Biosciences ( APRI), up 18.9%, Alliqua ( ALQA), up 17.1%, Tetraphase Pharmaceuticals ( TTPH), up 14.4% and Semler Scientific ( SMLR), up 13.1% , were all gainers within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical